"If they have a drug on the market, or they can show some positive results in 2016, are you not going to take this drug? I'm 60; give me this drug."
The drugmaker issued weaker-than-expected guidance for 2015, citing after-tax charges related to the acquisition of Locemia Solutions. Lilly also said it expects growth in 2016, excluding the impact of the strong dollar.
"In 2016 we expect multiple regulatory actions across therapeutic areas including diabetes, oncology and immunology," Derica Rice, the firm's chief financial officer, said in a statement Tuesday. "This will be another important year for execution of our innovation-based strategy, which will solidify our near- to medium-term growth prospects."
Shares of Lilly gained over 2.5 percent in morning trading after falling in the premarket.
DISCLOSURE: Cramer's trust did not own Lilly's stock when this article was published.